Title: Prevalence of asymptomatic glioma and implications for survival

- 2 Paula Province Warren¹, Mina Lobbous¹, Noah C. Peeri², Zachary J. Thompson³, Reid C.
- 3 Thompson⁴, Jeffrey J. Olson⁵, Renato V. LaRocca⁶, Sajeel A. Chowdhary⁷, Mark D. Anderson⁸,
- 4 Michael A. Vogelbaum⁹, James M. Markert¹⁰, Louis B. Nabors¹, and Kathleen M. Egan^{2*}
- ¹Neuro-oncology Program, University of Alabama at Birmingham, Birmingham, AL 35294
- ²Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute,
- 7 Tampa FL, 33612
- ³Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research
- 9 Institute, Tampa FL, 33612
- ⁴Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN
- 11 37232

1

- 12 ⁵Department of Neurosurgery, Emory School of Medicine, Atlanta, GA 30322
- 13 ⁶Norton Cancer Institute, Louisville, KY 40202
- ⁷Neuro-Oncology Program, Lynn Cancer Institute, Boca Raton, FL 33486
- ⁸Department of Neurology, the University of Mississippi Medical Center, Jackson, MS 39216
- ⁹Department of Neuro-oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa FL,
- 17 33612

19

26

29

30

- 18 ¹⁰Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294
- 20 *To whom correspondence should be addressed:
- 21 Kathleen M. Egan, ScD
- 22 Department of Cancer Epidemiology
- 23 Moffitt Cancer Center
- 24 12902 Magnolia Drive, Tampa, FL 33612
- 25 E-mail: kathleen.egan@moffitt.org
- 27 Short Title: Patient Survival in Asymptomatic Glioma
- 28 **Key Words:** glioma; incidentaloma; asymptomatic; epidemiology

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Abstract Background - Brain tumors can present as focal neurologic deficits (reflecting the tumor location) or generalized symptoms due to increased intracranial pressure. Occasionally, brain tumors can be found incidentally in asymptomatic patients or in patients with unrelated symptoms who undergo brain imaging. The term incidentaloma is used to refer to these imaging abnormalities. Objective - The object of this study was to examine the prevalence and correlates of asymptomatic glioma in a large epidemiological study of brain tumors. **Methods** - The analysis was based on a large series of patients with glioma (N = 1989) enrolled in a multicenter clinic-based epidemiologic study between 2005 and 2017. Patients were considered asymptomatic from the tumor, and thus as having an incidentally detected glioma (IDG), if the tumor was diagnosed during workup of injury or unrelated medical condition. **Results -** A total of 32 of 1989 (1.6%) patients were asymptomatic at diagnosis. The leading indication for brain imaging in IDG was non-workplace injuries followed by medical workup for unrelated conditions. IDG was more prevalent in patients younger than 50 years of age (2.6% vs 1.0%). IDG was also more common in patients with low grade gliomas (4.7% for WHO grade II and 1.5% for WHO grade III) vs glioblastomas (0.6% in WHO grade IV). **Conclusion -** The present data suggest that gliomas may be found incidentally, especially among low grade gliomas. Studies of IDG may be useful as a proxy for early detection of tumor as a means to improve patient survival.

Introduction

62

63 The majority of patients with brain tumors present with either focal or generalized symptoms. 64 Common presenting symptoms include seizures, symptoms of increased intracranial pressure, like headache and/or double vision, or focal neurologic deficits that depend on the intracranial 65 location of the tumor ¹. Some patients, however, are asymptomatic at the time of presentation 66 and have tumors that are incidentally discovered ². An "incidentaloma" is defined as an imaging 67 abnormality that is detected by chance in patients who undergo imaging for an unrelated medical 68 issue ^{3,4}. There has been a rapid rise in incidentaloma detection due to the increase in the number 69 of imaging scans performed as well as improvement in imaging resolution. Common reasons for 70 71 patients to undergo screening brain scans include trauma or medical workup for an unrelated condition. A 2009 systematic review of 16 studies in 19,559 patients reported the prevalence of 72 incidental neoplastic brain findings in MRI studies to be 0.7%, with the prevalence of glioma at 73 0.05% ⁵. Diffuse low-grade glioma may be radiologically detectable but clinically silent for more 74 than a decade ⁶. 75 Advances in molecular profiling and in the understanding of gliomagenesis has allowed for 76 improved diagnostic accuracy and better prognostic markers ^{7,8}. Although current 77 recommendations support early surgical resection for low-grade gliomas 9-13, management of 78 asymptomatic incidentally diagnosed gliomas remains a matter of debate. There are multiple 79 studies supporting moving away from the "watchful waiting" approach to earlier therapeutic 80 strategies ¹⁴⁻¹⁸. Pallud *et al* reported that incidental grade II gliomas were progressive in all cases 81 and transformed to symptomatic grade II gliomas at a median interval of 48 months after 82 radiological discovery and had malignant transformation at a median interval of 5.7 years after 83 radiological diagnosis ^{4,19}. In addition, the identification of an IDG offers insight into the natural 84 history of the disease prior to the time of neurological presentation. 85

Subjects and Methods

87 Study Population

- 88 The study population was comprised of 1,989 patients with a recent diagnosis of primary glioma
- 89 (ICD9/10: 191, C71), including glioblastoma (9440-9441) and WHO (World Health
- 90 Organization) grade II and III gliomas (9382, 9400-01, 9410-11, 9420, 9424-25, 9450-9451)^{20,21}

, enrolled in an epidemiologic study of glioma ²² ("GliomaSE") between 2005 and 2017. Patients were identified at neuro-oncology and neuro-surgery clinics at major medical centers in the Southeastern United States including Moffitt Cancer Center in Tampa, Florida; Kentuckiana Cancer Center (now Norton Cancer Institute) in Louisville, Kentucky; University of Mississippi Medical Center in Jackson, Mississippi; Emory University in Atlanta, Georgia; University of Alabama at Birmingham in Birmingham, Alabama; Morton Plant Hospital in Tampa, Florida; Vanderbilt University Medical Center in Nashville, Tennessee; Florida Hospital in Orlando, Florida; and Boca Raton Regional Hospital in Boca Raton, Florida). The study was approved by Investigational Review Committees at each participating center and all subjects provided written informed consent. Clinical data including presenting signs and symptoms were collected from neuro-oncology reports. Cause of death and follow-up for vital status were obtained through review of medical records, hospital registries, and a search of the National Death Index.

Symptoms at Presentation

Medical records for all patients were reviewed for first signs and symptoms of tumor presentation. Symptoms included headache, change in vision or hearing, focal weakness or numbness, memory loss, personality changes, speech difficulties, dizziness or loss of balance, gait or walking difficulties, confusion, and seizure. Patients were considered asymptomatic if the tumor was diagnosed incidentally during work-up for an injury or other non-related medical or surgical conditions. Neuro-oncology notes for each suspected IDG were reviewed by a board-certified neuro-oncologist (PPW). Cases in which events surrounding diagnostic neuroimaging were potentially related to early manifestations of the tumor (for example, a fall with head injury preceded by apparent seizure) were excluded from the IDG category.

Statistical Analysis

Associations between symptom status at presentation and demographic and clinical factors were assessed with Monte-Carlo estimates of exact *chi-square* test p-values. Logistic regression was used to estimate Odds Ratios (OR) and 95% Confidence Intervals (CI) relating clinical factors to IDG. Multivariable models included terms for tumor grade (Glioblastoma WHO grade IV, WHO grade III, and WHO grade II), gender, and patient age (<50 and >=50 years of age). To evaluate relationships with survival, we selected 1 to 3 symptomatic patients matched to each IDG patient

on age at diagnosis (within 5 years), date of diagnosis (within 18 months), and tumor subtype (WHO grade II, III, and IV). Conditional Cox proportional hazards regression was used to estimate the Hazards Ratio (HR) and 95% CIs for IDG with adjustment via matching for age at diagnosis, date of diagnosis, and tumor subtype with observation beginning at first presentation of the tumor.

Results

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

A total of 32 of 1989 (1.6%) patients were asymptomatic from the tumor at diagnosis. Circumstances surrounding incidental glioma diagnosis are summarized in **Table 1**. The leading indications were non workplace-related injuries (n=7; examples: patient hit by a falling tree branch), followed by diagnoses made during medical work-up for unrelated diseases or conditions (n=6; examples: sleep apnea; progressive Parkinson's disease with dementia) and motor vehicle accidents in which the patient was not the driver or judged to be at fault (n=5; example: rear-ended by speeding car). Other categories included pre-operative workup for unrelated CNS surgery (n=1; pre-op for lumbar surgery); surveillance imaging after surgical repair of cerebral aneurysm (n=1, 6 month surveillance scan status-post left middle cerebral artery aneurysm clipping); examination for substance abuse (n=2; example: alcohol withdrawal and fentanyl overdose); infectious disease workup (n=2; viral meningitis and Epstein Barr mononucleosis); hypertension or diabetes workup (n=2; unexplained severe hypertension and uncontrolled diabetes); injury at work (n=2; example: hit in the head by falling box); peripheral neuropathy (n=1; neuropathy due to entrapment of ulnar nerve); unexplained dizziness (n=1; dizziness following brachytherapy for prostate cancer); infertility workup (n=1; related to increased levels of prolactin); and routine eye exam (n=1; papilledema observed during yearly eye exam in a patient with no noted symptoms).

Associations between symptom status at presentation and demographic and clinical factors are shown in **Table 2**. Prevalence of IDG was significantly higher in patients under 50 years of age (2.6%) than patients 50 years or older (1.0%). IDG was more common with progressively lower tumor grade: 0.6% for glioblastoma; 1.5% for WHO grade III; and 4.7% for WHO grade II. No

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

significant differences were observed by gender, race, state of residence, education, or hemispheric location of the tumor. **Table 3** presents results from multivariable logistic regression considering factors associated with IDG. WHO grade II was associated with an over seven-fold increased prevalence of IDG (OR: 7.53; 95% CI: 2.87, 19.7) while controlling for gender and age. Neither age nor gender was independently associated with IDG after adjustment for tumor grade. Results of conditional Cox proportional hazards regression of IDG in relation to tumor-related death are shown in **Table 4**. HRs were estimated among 28 IDG patients and 63 individually matched symptomatic patients. (No suitable match could be identified in 4 of the 32 IDG patients.) As shown in Table 4, the hazard of dying was significantly reduced by ~50% (HR: 0.49; 95% CI: 0.26, 0.95; p=0.035) in IDG adjusting through matching for age at diagnosis, date of diagnosis, and tumor subtype. Reduction in death rates was more pronounced when restricting to WHO grade II glioma (17 IDG and 36 symptomatic patients) (HR: 0.18; 95% CI: 0.03, 1.01; p=0.051) though results were based on limited data (1 death occurring among 17 IDG patients). In 14 of 28 matched sets, the IDG patient and controls were concordant for resection (N=11 sets) or biopsy-only (N=3 sets) whereas the remaining 14 sets were discordant for extent of surgery (in 12 of the 14 sets, the IDG patient underwent resection whereas the controls underwent biopsy-only). When restricting to the 14 matched sets concordant for surgery (comprised of 6 GBMs, 3 grade III gliomas, and 5 grade II gliomas), HRs were attenuated and no longer statistically significant (HR: 0.85; 95% CI: 0.42, 1.72; p=0.212). Among the 5 matched sets comprised of WHO grade II gliomas, 0/5 IDG and 5/11 symptomatic patients died from glioma during the observation period. **DISCUSSION** The long-running clinic-based epidemiologic study, GliomaSE, offers a unique opportunity to describe the prognosis and natural history of subsets of patients with glioma. These subsets may offer insights as well as the generation of new hypotheses related to the course of these diseases. The study population is reflective of the population of patients with primary glioma diagnosed in the southeastern United States and genotyping of the study population has yielded results ^{15,23} in concordance with published glioma GWAS ²⁴.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

In the present study, we observed that as many as 5% of grade II gliomas are asymptomatic at presentation. Tumor grade is an overwhelming predictor of IDG, with a 7.5-fold excess of IDG in grade II tumors and nonsignificant 2.4-fold excess in grade III tumors when compared to glioblastoma. IDG was unrelated to patient age or gender in multivariate regression analyses after adjustment for tumor grade. The present study raises the possibility that IDG is associated with a longer survival interval following presentation among grade II tumors only although only tentative conclusions can be reached given the limited number of IDG patients available for analysis. Previous studies of IDG included tumors that came to attention during workup for headache ^{18,25}-²⁷. We elected to exclude such cases as there was no instance in our series of a tumor detected in persons with a long-standing headache disorder during a purely 'routine' imaging study. Rather, headaches leading to diagnosis were described by such persons as acutely worsening or of a 'different character' as compared to headaches usually suffered by the patient and this in turn prompted diagnostic work-up and detection of the tumor. We therefore classified such patients as 'symptomatic'. The study had some limitations. In spite of the large patient series, suitable matches in the survival analyses were not identified for several of the IDG patients (4 of 32). Furthermore, only 14 of the remaining 28 sets had controls matched also for tumor resection, a positive prognostic factor when compared to biopsy only ^{11,12,28}. When restricting analysis to these 14 matched sets concordant for surgery type (all members of the matched set undergoing resection or biopsy), reduced mortality in IDG patients was greatly attenuated (HR=0.85) (not shown). We note that the latter result was based predominately on higher grade tumors (9 of 14 pairs had a grade III astrocytoma or GBM), and it is possible that earlier detection via incidental diagnosis is associated with survival benefit only in low-grade tumors: as noted, among the 5 matched sets comprised of WHO grade II gliomas, 0/5 IDG and 5/11 symptomatic patients died from glioma during the observation period. Of note, a recent study published by Ius et al examining incidentally discovered low-grade gliomas did show that incidentally detected low grade gliomas had a longer overall survival than symptomatic low grade gliomas, even when a complete surgical resection was obtained ²⁷.

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

For most patients in this series, we lacked information on IDH mutation status which is a key prognostic feature of the low-grade tumors that comprised the majority of IDG patients in this study. (Most patients were diagnosed prior to the modern IDH1 era). IDH1 has been linked to improved patient survival^{8,29,30}. In the present survival analysis, 39 of 91 patients had known IDH1 status, and mutated IDH1 was observed in a slightly higher proportion of IDG patients (52.9%, n=9 of 17) than non-IDG controls (40.9%, n=9 of 22) (p=0.43); among patients with WHO grade II tumors, 6/9 IDG and 4/10 symptomatic tumors were positive for *IDH1*. Incidentalomas in GBM are rare and the potential impact on patient survival is poorly studied. Restricting to the 6 matched sets (5 GBM and 1 grade III astrocytoma) in which all members underwent resection within 3 months of tumor detection (mean: 27 days from presentation to surgery), IDG patients survived no longer (mean of 19.6 months; n=6) than the symptomatic patients (mean of 24.4 months; n=16); though based on limited data, these results suggest that incidental detection of the tumor does not extend survival in patients with high grade tumors. The literature suggests that early identification of low-grade glioma is associated with improved outcomes as it is easier to operate on a smaller lesion ^{10,31,32}. In addition, by detecting tumor prior to the onset of neurological signs and symptoms the burden of disease is the least on a patient and the opportunity for preserved neurological function remains the highest. The difference in survival outcome in this report supports efforts to identify risk factors associated with glioma. There is increasing support for a moderate role of genetic susceptibility through the identification of risk alleles ²⁴. As further efforts define the biological significance of known risk variants and potentially expand this pool, genetic risk screening with targeted imaging may provide improved outcomes for patients, particularly the young adult with a low-grade glioma. This study provides some additional support for the developing evidence favoring early detection programs, "tailored screening," and active management 33 which may include consideration of surgical resection, chemotherapy, radiotherapy, along with molecular and histopathologic characterization.

References:

- 245 1. DeAngelis LM. Brain Tumors. N Engl J Med. 2001;344(2):114-123.
- 2. Mandonnet E, de Witt Hamer P, Pallud J, Bauchet L, Whittle I, Duffau H. Silent diffuse low-grade glioma: Toward screening and preventive treatment? *Cancer.* 2014;120(12):1758-1762.
- 248 3. O'Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA. Prevalence and outcomes of incidental imaging findings: umbrella review. *BMJ.* 2018;361:k2387.
- 4. Katzman GL, Dagher AP, Patronas NJ. Incidental Findings on Brain Magnetic Resonance Imaging From 1000 Asymptomatic Volunteers. *JAMA*. 1999;282(1):36-39.
- 5. Morris Z, Whiteley WN, Longstreth WT, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ.* 2009;339:b3016.
- 254 6. Pallud J, Capelle L, Taillandier L, Badoual M, Duffau H, Mandonnet E. The silent phase of diffuse low-grade gliomas. Is it when we missed the action? *Acta neurochirurgica*. 2013;155(12):2237-256 2242.
- 257 7. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. *Neuro Oncol.* 2013;15(4):469-479.
- Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. *N Engl J Med.* 2009;360(8):765-773.
- Nabors LB, Portnow J, Ammirati M, et al. NCCN Guidelines Insights: Central Nervous System
 Cancers, Version 1.2017. *Journal of the National Comprehensive Cancer Network*.
 2017;15(11):1331-1345.
- Duffau H. The Rationale to Perform Early Resection in Incidental Diffuse Low-Grade Glioma:
 Toward a "Preventive Surgical Neurooncology". World Neurosurgery. 2013;80(5):e115-e117.
- Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a Strategy Favoring Early Surgical Resection
 vs a Strategy Favoring Watchful Waiting in Low-Grade GliomasSurgical Resection vs Waiting in
 Low-Grade Gliomas. JAMA. 2012;308(18):1881-1888.
- McGirt MJ, Chaichana KL, Attenello FJ, et al. EXTENT OF SURGICAL RESECTION IS
 INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITH HEMISPHERIC INFILTRATING
 LOW-GRADE GLIOMAS. Neurosurgery. 2008;63(4):700-708.
- Compton JJ, Laack NNI, Eckel LJ, Schomas DA, Giannini C, Meyer FB. Long-term outcomes for
 low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic: Clinical article.
 Journal of Neurosurgery. 2012;117(5):825-830.
- 275 14. Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. *Acta neurochirurgica*. 2012;154(4):575-584.
- Egan KM, Thompson RC, Nabors LB, et al. Cancer susceptibility variants and the risk of adult glioma in a US case-control study. *J Neurooncol*. 2011;104(2):535-542.
- Lima GLdO, Zanello M, Mandonnet E, Taillandier L, Pallud J, Duffau H. Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery. *Neurosurg Rev.* 2016;39(3):377-384.
- Potts MB, Smith JS, Molinaro AM, Berger MS. Natural history and surgical management of incidentally discovered low-grade gliomas: Clinical article. *Journal of Neurosurgery*.
 2012;116(2):365-372.
- Wright E, Amankwah E, Winesett SP, et al. Incidentally found brain tumors in the pediatric population: a case series and proposed treatment algorithm. *Journal of neuro-oncology.* 2018.
- 287 19. Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental world health organization grade II gliomas. *Annals of Neurology*. 2010;68(5):727-733.
- 289 20. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. *Acta Neuropathol.* 2007;114(2):97-109.

- 291 21. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016;131(6):803-820.
- Egan KM, Thompson RC, Nabors LB, et al. Cancer susceptibility variants and the risk of adult glioma in a US case—control study. *Journal of neuro-oncology*. 2011;104(2):535-542.
- 295 23. Egan KM, Nabors LB, Olson JJ, et al. Rare TP53 genetic variant associated with glioma risk and outcome. *Journal of medical genetics*. 2012;49(7):420-421.
- 24. Kinnersley B, Houlston RS, Bondy ML. Genome-Wide Association Studies in Glioma. Cancer
 298 epidemiology, biomarkers & prevention: a publication of the American Association for Cancer
 299 Research, cosponsored by the American Society of Preventive Oncology. 2018;27(4):418-428.
- Lim J, Park Y, Kim MJ, Ahn J, Cho Kg. SURG-31. INCIDENTAL LOW GRADE GLIOMAS: "WAIT AND
 SEE" OR "SURGERY". Neuro Oncol. 2017;19(suppl_6):vi241-vi241.
- 302 26. Opoku-Darko M, Lang S, Kelly J, Cadieux M. P.021 Surgical management of incidentally
 303 discovered diffusely infiltrating glioma. *Canadian Journal of Neurological Sciences*.
 304 2017;44(S2):S19-S19.
- 305 27. Ius T, Cesselli D, Isola M, et al. Incidental Low-Grade Gliomas: Single-Institution Management 306 Based on Clinical, Surgical, and Molecular Data. *Neurosurgery*. 2019.
- Berger MS, Rostomily RC. Low grade gliomas: Functional mapping resection strategies, extent of resection, and outcome. *Journal of neuro-oncology*. 1997;34(1):85-101.
- 29. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med.* 2015;372(26):2499-2508.
- 30. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. *Neurology*. 2010;75(17):1560-1566.
- 31. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults: A review. *Journal of Neurosurgery*. 2011;115(5):948-965.
- 32. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma. *Journal of neuro-oncology*. 2015;125(3):503-530.

318 33. Pouratian N, Schiff D. Management of low-grade glioma. *Current neurology and neuroscience reports.* 2010;10(3):224-231.

Table 1. Circumstances of incidental glioma diagnosis

Reason for incidental diagnosis	N (%)
Nonworkplace injury	7 (21)
Follow up for unrelated medical condition	6 (19)
Motor vehicle accident	5 (16)
Preoperative examination	2 (6)
Substance abuse examination	2 (6)
Infectious disease workup	2 (6)
Hypertension and/or diabetes workup	2 (6)
Workplace injury	2 (6)
Peripheral neuropathy workup	1 (3)
Unexplained dizziness	1 (3)
Infertility workup	1 (3)
Routine eye exam	1 (3)

Table 2. Descriptive statistics and symptoms at presentation in 1989 glioma patients

		Symptomatic at Presentation*		
Variable	Level	Yes (n=1957)	No (n=32)	p-value
Age at Diagnosis	<50 ≥ 50	762 (97.4%) 1195 (99.0%)	20 (2.6%) 12 (1.0%)	0.01
Gender	Female Male	826 (98.7%) 1131 (98.2%)	11 (1.3%) 21 (1.8%)	0.47
Race	Caucasian African American Asian or Pacific Islander	1820 (98.3%) 106 (99.0%) 24 (100.0%)	31 (1.7%) 1 (1.0%) 0 (0.0%)	0.82
State	AL FL KY Other	340 (98.8%) 885 (98.1%) 158 (96.3%) 574 (99.1%)	4 (1.2%) 17 (1.9%) 6 (3.7%) 5 (0.9%)	0.06
Education	≤12 years >12 years	652 (98.2%) 1183 (98.3%)	12 (1.8%) 20 (1.7%)	0.85
Hemisphere	Right Left Bilateral	934 (98.2%) 941 (98.5%) 35 (97.2%)	17 (1.8%) 14 (1.5%) 1 (2.8%)	0.86
Histology	GBM Grade III Grade II	1245 (99.4%) 323 (98.5%) 389 (95.3%)	8 (0.6%) 5 (1.5%) 19 (4.7%)	<0.01

^{*}Unequal column totals reflect missing data

Table 3. Multivariate regression of clinical variates and asymptomatic presentation (N=1989)

Category	Exposure	No. asymptomatic	OR*	95% CI*	p-value
Tumor Grade	GBM	8	referent	-	-
	Grade III	5	2.41	(0.75, 7.68)	0.14
	Grade II	19	7.53	(2.87,19.75)	<0.01
Gender	female	11	referent	-	-
	male	21	1.47	(0.70, 3.08)	0.31
Age at Dx	<50	20	referent	-	-
	>=50	12	0.96	(0.42, 2.23)	0.93

^{*}OR= odds ratio; CI=confidence interval. ORs/CIs adjusted for other terms included in the table.

Table 4. Association of asymptomatic presentation with survival in matched analysis

Parameter	HR	95% CI	P-Value
IDG vs. symptomatic gliomas ¹	0.49	(0.26, 0.95)	0.0349

Hazard ratio (HR) and 95% confidence interval (CI) for incidental glioma diagnosis (IDG) adjusted via matching for age at diagnosis (within 5 years), date of diagnosis (within 18 months), and tumor subtype (grade II, III or GBM). A total of 28 IDG and 63 individually-matched symptomatic patients were included in the analysis (no suitable match could be identified for the remaining 4 IDG patients).